Exhibit 107

Calculation of Filing Fee Tables

Form S-3

(Form Type)

Bolt Biotherapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

Security Type

Security Class Title

Fee Calculation or Carry Forward Rule

Amount Registered

Proposed Maximum Offering Price Per Unit

Maximum Aggregate Offering Price

Fee Rate

Amount of Registration Fee

Carry Forward Form Type

Carry Forward File Number

Carry Forward Initial effective date

Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward

Newly Registered Securities

Fees to Be    Paid

Debt

Debt Securities(1)

Equity

Preferred Stock, par value $0.00001 per share(1)

Equity

Common Stock, par value $0.00001 per share(1)

Other(5)

Warrants(1)

Unallocated (Universal) Shelf

457(o)

(2)

(3)

$

250,000,000

$

0.0000927

$

23,175(4)

Fees    Previously    Paid

Carry Forward Securities

Carry    Forward    Securities

Total Offering Amounts

$

250,000,000

$

0.0000927

$

23,175

Total Fees Previously Paid

N/A

Total Fee Offsets

N/A

Net Fee Due

$

23,175

(1) Separate consideration may or may not be received for securities that are issuable upon the conversion or exercise of, or in exchange for, other securities offered hereby.

(2) There are being registered hereunder such indeterminate number of shares of common stock and preferred stock, such indeterminate principal amount of debt securities and such indeterminate number of warrants to purchase common stock, preferred stock and/or debt securities to be sold by the Registrant from time to time at unspecified prices which shall have an aggregate initial offering price not to exceed $250,000,000. The securities registered for sale also include such indeterminate number of shares of common stock and preferred stock and amount of debt securities as may be issued upon conversion of or exchange for preferred stock or debt securities that provide for conversion or exchange, upon exercise of warrants or pursuant to the antidilution provisions of any such securities.

(3) The proposed maximum offering price per share will be determined, from time to time, by the Registrant in connection with the issuance by the Registrant of the securities registered hereunder and is not specified as to each class of security pursuant to General Instruction II.D. of Form S-3 under the Securities Act.

(4) The proposed maximum aggregate offering price has been calculated pursuant to Rule 457(o) under the Securities Act.